Boundless Bio (BOLD) Stock: Buy, Sell, or Hold?
BOLD - Boundless Bio, Inc. Common Stock
$2.83
-0.01 (-0.35%)
âŧ
5d:
-1.39%
30d:
+1.8%
90d:
+103.6%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When BOLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BOLD is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BOLD is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: BOLD is currently trading at $2.83, which is considered fair relative to its 30-day fair value range of $2.80 to $2.91.
Technical Outlook: Technically, BOLD is in a strong uptrend. The price is currently testing key support at $2.76. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BOLD scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+41.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BOLD is in a strong uptrend. The price is currently testing key support at $2.76. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BOLD scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+41.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.80 -
$2.91
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 41.3% below Wall St target ($4.00)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.80 -
$2.91
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.76
Resistance Level
$2.94
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.89
Wall Street Target
$4.00
(+41.3%)
Share & Embed Analysis
Last updated: September 13, 2026 4:10 AM ET
Data refreshes hourly during market hours. Next update: 5:10 AM
Data refreshes hourly during market hours. Next update: 5:10 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BOLD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
